Purpose: To examine differences in opioid prescribing by patient characteristics and variation in hydrocodone combination product (HCP) prescribing attributed to states, before and after the 2014 Drug Enforcement Administration's reclassification of HCP from schedule III to the more restrictive schedule II.
| INTRODUCTION
The rise in the prescribing of opioid analgesics for chronic noncancer pain over the last decade has contributed to the epidemic of opioid-related addiction, overdose, and mortality in the US. [1] [2] [3] [4] State laws and federal policies implemented to curb this epidemic have had varying effects. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The prescribing of schedule II opioids (classified as high abuse potential) is more tightly regulated by federal rules. Individual states have more input in regulating the prescribing of schedule III opioids (classified as moderate abuse potential). For example, states can make additional laws to make schedule III opioids prescribing almost as restrictive as schedule II. 5, 7, [9] [10] [11] [12] [13] [14] Previous studies showed that inter-state variation was smaller for schedule II than for schedule III opioids, suggesting a larger impact of federal policies on the former. 7, 10 In 2014, the Drug Enforcement Administration (DEA) reclassified all hydrocodone combination products (HCP), the most frequently prescribed opioids in the US, from schedule III to schedule II. [15] [16] [17] This limited all new HCP prescriptions to a maximum 30-day supply with no refills. A study based on data from US pharmacies showed a 22% decline in hydrocodone combination prescriptions and a 5% increase in non-hydrocodone opioid prescriptions within 12 months of the 2014 federal DEA policy. 18 Studies from single center health systems or poison centers reported similar changes. [19] [20] [21] [22] [23] [24] The current study used data for patients aged 18 to 64 years from a large national commercial health insurance program to examine the impact of the 2014 federal policy on opioid prescribing by patient characteristics and across states.
Studying the effect of the 2014 federal policy in this population is important because persons aged 18 to 64 represent a high-risk population for opioid-related toxicity. 25, 26 This population demonstrated a significant and progressive increase-from 2003 to 2013-in the prevalence of prescription opioid use disorders, frequency of use, and overdose deaths. 26 In addition, the commercial insurance cohort under study represents a population with considerable access to prescription opioids. Any policy that restricts prescribing or affects refilling of specific prescription opioids, as in the 2014 federal policy, has potential to affect prescribing of opioid analgesics in this population.
We hypothesized that the 2014 federal policy would be associated with declines in HCP prescribing. We also hypothesized that there would be a larger decrease in HCP prescribing for non-cancer pain patients than for cancer patients. 2, 3, 15 Lastly, we hypothesized that there would be a decrease in the state-to-state variation in HCP prescribing with the increase in federal regulation.
| METHODS

| Study design and data sources
We conducted a retrospective cohort study using de-identified administrative health data from Clinformatics Data Mart™ (CDM, Optum
Insight, Eden Prairie, MN). 27 Data analyzed were from the following:
the Member file, which includes information on demographic factors, region of residence, and insurance enrollment date; the Medical file, which includes all inpatient and outpatient encounter information, including diagnosis codes, procedure codes, and encounter dates; and the Pharmacy file, which includes medication name, date of fill, formulation, dose, quantity, and days of supply.
| Study population and variables of interest
During the study period (January 1, 2013 through December 31, 2015), 9 202 958 persons aged 18 to 64 years met the study's inclusion criterion of having at least 13 months of continuous coverage.
| MEASURES
| Opioid prescribing
We used National Drug Code therapeutic class description and DEA class code from the 2015 RedBook Select Extracts database, to classify opioid treatment into HCP, non-hydrocodone schedule II opioids, nonhydrocodone schedule III opioids, and tramadol. 28 Tramadol was in its own comparator category because prior studies showed a shift in prescribers' behavior with a substitution of the less-restricted tramadol for the newly up-scheduled HCP. [18] [19] [20] [21] [22] 24 The unit of measurement is the prevalence of opioid prescription defined as any opioid prescribed to enrollees, with at least 1 opioid prescription in the study year. 
| Patient characteristics
Patient age was categorized at each month of observation. Race or ethnicity is not reported in the CDM. We examined all conditions included in the Elixhauser comorbidity index, with the exception of cancer, using a 12-month lookback period. 29 The Elixhauser comorbidity index comprises 30 conditions including drug and alcohol abuse, depression, and psychoses. 29 Patients were classified as having cancer if they had an International Classification of Diseases, ninth revision, clinical modification (ICD-9-CM) diagnosis code for any solid cancer or leukemia/lymphoma with the exception of non-melanoma skin cancers (eTable 1). 30 Among patients with cancer, those who received radiation or chemotherapy treatment and those who were hospitalized with a primary diagnosis of cancer in the prior year were classified as "actively treated."
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KEY POINTS
• Data from 9 202 958 privately insured patients aged 18
to 64 were used to examine opioid prescribing rates before and after the 2014 federal hydrocodone combination product (HCP) rescheduling policy.
• HCP prescribing decreased by 26% from 2013 to 2015;
any opioid prescribing decreased by 11%; and variation by state of residence increased substantially.
• Patients with multimorbidities and actively treated cancer patients had the largest decreases in HCP prescribing.
• The large decrease in HCP prescribing in actively treated cancer patients may represent an unintended consequence.
| Statistical analysis
The in June 2015, an 11.42% reduction (P < 0.0001). Table 1 We next examined the decrease in HCP prescribing as a function of specific patient characteristics (Table 2 ). For this, we compared Note: All the characteristics were significant at 0.01 level.
Trt. = Treatment. quintiles. There were also large differences in the relative changes in use among states, from a 46.7% decrease in Texas to a 12.7% increase in South Dakota (eTable 2).
We further examined the variation among states in HCP prescribing before and after the change in regulations using a multilevel model to estimate intra-class correlation coefficients indicating the proportion of variance in HCP prescribing attributed to the state of residence.
Variation attributable to state was actually higher after the change in Unlike the previously reported increase in tramadol prescribing after the 2014 HCP up-scheduling, [14] [15] [16] [17] [18] [19] [20] we did not find this increase in our study population. Our national cohort included men and women aged <65 with access to commercial insurance that covers prescription medications. Most prior studies were based on predominantly indigent, pediatric, or veteran populations or from single health systems, hospitals, or poison centers. 16, 32, 33 It is possible that commercial health insurance medication carriers have specific programs to blunt the substituting of one opioid for another, as reported in prior studies. [18] [19] [20] [21] [22] [23] [24] 34 In particular, the health insurance carrier for the population who contributed data for our study implemented several programs (eg, limiting number of refills of any opioid and requiring prior authorization) to reduce inappropriate opioid prescribing among its enrollees. 34 It is thus possible that the upticks in tramadol prescribing previously reported in other studies were mitigated in our sample by the impact of these programs.
Consistent with prior studies, increasing age, female gender, and high comorbidity scores were associated with higher rates of HCP prescribing. 7, [35] [36] [37] Patients with higher comorbidity scores had the highest initial rate of receiving prescribed opioids, and their absolute decreases were greatest. Actively treated cancer patients had substantially larger absolute reductions and similar relative reductions in the rate of HCP prescribing compared with non-cancer patients. 24, 38, 39 Several studies have raised concerns about the potential for unintended consequences of the federal policy on the adequacy of pain treatment in cancer patients undergoing chemotherapy and other cancer-specific interventions. 24, [39] [40] [41] [42] There were large inter-state variations in both the absolute and relative changes in the rates of HCP prescribing before and after the consumed. Finally, information on race, ethnicity, and socioeconomic status was not available for the study population. Past studies showed an association of socio-demographic factors with rates of use, misuse, and toxicity of prescription and non-prescription opioids. 25, [45] [46] [47] Our study also has important strengths, including a large sample size in all US states. The present study added to the existing body of literature in by improving our understanding of (1) This may represent an unintended consequence of the federal policy on the adequacy of pain treatment in cancer patients. It will be important to assess whether the restriction of hydrocodone prescribing increase the rates of illicit opioid use.
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